Tokyo - Gene Techno Science Co., Ltd. ('GTS') completed the issuance of the 3rd series of convertible bond with stock acquisition rights and the 10th series of stock acquisition rights to CVI Investments, Inc. and confirmed the payment of the fund.

This fund will be used mainly for promoting JRM-001 aiming at improving cardiac functions on post-surgery. (This project will be led by Japan Regenerative Medicine Co., Ltd. which is now a 100% affiliate of GTS.)

About Gene Techno Science Co., Ltd. GTS announced GTS 3.0 'Biotech Engineering Company, striving for value creation' a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Tel: +81-3-6222-9547

Email: info@g-gts.com

(C) 2020 Electronic News Publishing, source ENP Newswire